Skip to main content
SpringerLink
Log in

Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion

  • Chapter
Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 438))

Abstract

Cyclosporine A (CsA) is an immunomodulator that inhibits T-cell mediated immunoreactivity.1–4 In addition, data indicate that CsA may act as an anti-inflammatory, due to its phosphatase inhibition activity. Because of these actions, CsA ophthalmic emulsion formulation was developed by Allergan for treatment of keratoconjunctivitis sicca. Since the safety profile of this new formulation is very important for the clinical success of the drug, long-term safety studies were carried out as described below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effect of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976; 6: 468–475.

    Article  PubMed  CAS  Google Scholar 

  2. Bord JF. Cyclosporine: historical perspectives. Transplant Proc. 1983; 15: 3–13.

    Google Scholar 

  3. Shevach EM. The effects of cyclosporine A on the immune system. Annu Rev Immunol. 1985; 3: 397–423.

    Article  PubMed  CAS  Google Scholar 

  4. Kahan BD, Bach JF (eds). Proceedings of the Second International Congress on Cyclosporine. Transplant Proc. 1988;20, Suppl. 3: 1–1131.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Allergan, Irvine, California, USA

    O. Angelov, A. Wiese, Y. Yuan, J. Andersen, A. Acheampong & B. Brar

Authors
  1. O. Angelov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Wiese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Acheampong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Brar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA

    David A. Sullivan  & Darlene A. Dartt  & 

  2. Louisiana State University Medical Center, New Orleans, Louisiana, USA

    Michele A. Meneray

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Angelov, O., Wiese, A., Yuan, Y., Andersen, J., Acheampong, A., Brar, B. (1998). Preclinical Safety Studies of Cyclosporine Ophthalmic Emulsion. In: Sullivan, D.A., Dartt, D.A., Meneray, M.A. (eds) Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. Advances in Experimental Medicine and Biology, vol 438. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5359-5_142

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5359-5_142

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7445-9

  • Online ISBN: 978-1-4615-5359-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation